MedPath

Comparative evaluation of teraputic effects (improving indicators) related to Recurrent HerpesLabialis using Nano and mocoadhesive formulation of acyclovir and acyclovir_clobetasole

Early Phase 1
Conditions
Recurrent herpes labialis.
Registration Number
IRCT20230926059521N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

(The lesion is recurrent (secondary) and not primary in any case. 2) The age range of the patient should be between 18 and 60 years. does not. 5) The patient should not use any lip moisturizing topical cosmetics or sun cream in the lesion area during the treatment, and should not perform any manipulations such as scratching or facial modification in the area. 6) The lesion should be in the papule-vesicle stage

Exclusion Criteria

Having an allergy to acyclovir or a history of severe allergy to other drugs. 2) Using topical or systemic drugs to treat recurrent herpes labialis in the last 4 weeks. 3) Suffering from systemic diseases or liver and kidney failure diseases. 4) Using Contraceptive pills and breastfeeding. 5) suffering from immunodeficiency and acquired diseases

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The amount of pain or burning was calculated and recorded by the patient with a score scale, and the time of dressing the scab and recovery time was recorded by the clinician. Timepoint: 1st to 7th day after delivery of medicine. Method of measurement: The amount of pain or burning was calculated and recorded by the patient with a score scale, and the time of dressing the scab and recovery time was recorded by the clinician.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath